All News
More thoughts from @ashira_md's talk on Gaslighting/microaggressions from #ACR21 ...
(Q 1/2)
Providers: have you ever been told you are difficult and/or challenging?
Elizabeth Graef SituationRheum ( View Tweet)
Abst 1661
Scheir & colleagues identified patterns of multimorbidity and association w/ disability in patients w/ early RA
- In women: Depression significantly associated w/ disability
- In men: HTN & Lung Disease significantly associated w/ disability
#ACR21 @RheumNow https://t.co/0qkn1TcvOi
Akhil Sood MD AkhilSoodMD ( View Tweet)
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY
Janet Pope Janetbirdope ( View Tweet)
#ACR21 #AbstrL21 Phase III RCT which stratified pts using FFS showed no superiority of Rituximab vs SOC for remission induction of EGPA #vasculitis at Day 180 (63.5% vs 60.4%). No difference in secondary endpoints, safety or subgroup analyses @RheumNow https://t.co/AbdAvlU0Bg https://t.co/yta1CM7hrs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm
Janet Pope Janetbirdope ( View Tweet)
Cycling bDMARDs in #PsA. Law of diminishing returns. The more you fail, the more you cycle BUT can we break cycle by ⬆️adherence & health literacy, d/c smoking, use drug levels, biomarkers. Oh that in in future #ACR meetings! #ACR21 abst#1830 @RheumNow https://t.co/GyhgUGHWe8
Janet Pope Janetbirdope ( View Tweet)
Canadian study found no significant differences in effectiveness or tx survival among different TNFi, or in nr-axSpA or AS. Failure of 1st TNFi didn't diminish effectiveness or drug survival of additional TNFi. Abs 0938 #ACR21 #RheumNow @RheumNow https://t.co/u1efnfv2zA https://t.co/qsJw3nA9qn
Dr. Rachel Tate uptoTate ( View Tweet)
Handy overview of Jak/STAT pathways in rheumatic diseases and available inhibitors (Dr. Joost Swart). Happening now in the Pediatrics Hub (New Therapies & Biologic Safety in Pediatric Rheumatology). #ACR21 #pedsrheum https://t.co/i4bYr4GKOP
Katie Poholek kpoho ( View Tweet)
Similar effects in those with CKD stage 3, with also high proportion of achieving serum urate target <6mg/dL (overall 99% of study sample achieved target during trial) https://t.co/gKvDJKoWuw
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
OA oral session - abstract 1904
Devin Driscoll (mentor @tuhina_neogi) presenting data from MOST:
Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement
#ACR21 https://t.co/APZAJdHH5M
Rheum Cat rheum_cat ( View Tweet)
Dr Ami Shah - Scleroderma & Cancer:
🛑 ⬆️ risk of ca around the time of dx in SSc patients with RNA-pol-III (especially first 5 years after dx), anti-Th/To protective?
🛑Her approach for ca screening in newly diagnosed with SSc pts and red flags as below
#ACR21 #ACRambassador https://t.co/2VcWn2UInm
Didem Saygin, MD didemsayginmd ( View Tweet)
IL17 IS Impt in giant cell arthritis. Who would’ve thought that #secukinumab would treat #GCA? More options for pts. Only 52 pts but maybe another Rx for GCA? #ACR21 abst#L19 https://t.co/dwbPmGswQ9
Janet Pope Janetbirdope ( View Tweet)
Hair Loss due to Methotrexate from RCTs in RA estimated at 6.9%.
It's an understandable source of concern for those taking the medication
#ACR21 https://t.co/GymV2RC7jT
Dr Irwin Lim _connectedcare ( View Tweet)
@ashira_md blazing through again! Tune in now to hear her talk on #microaggressions and #gaslighting
#ACR21 #ACRAmbassador #DEI https://t.co/uqvLxxcs43
Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)
🆕 Main findings of #Lupus trials presented at #ACR21 ⬇️ https://t.co/HENxcyLuf5
Laurent ARNAUD Lupusreference ( View Tweet)
🗳️Poll of the day for #ACR21 #ACRambassador
@ACRheum
🤔What format do you prefer for #ACR22?
Herman Tam DrPedsRheum ( View Tweet)
Dr. Lane on Ca/Vitamin D in Osteoporosis
⭐️🎯serum vitamin D 25OH ~38
⭐️Studies since 2008 Auckland Calcium trial DO NOT support incr CV risk with Ca supplementation
⭐️Ca calculator: https://t.co/PLPMfZdIwb
⭐️No sig change in fracture risk with supp
#ACR21 #ACRAmbassador https://t.co/KUa52vf4gT
Veena Katikineni VeenaRheumMD ( View Tweet)
Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more!
#ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni VeenaRheumMD ( View Tweet)
Thanks Dr David Fiorentino for his talk on CA and myositis!
⬆️risk:
- DM
- >45-50yo
- males
- TIF1-gamma Ab (4.7RR of CA)
- NXP2
- low CK
- dysphagia
⬇️ risk:
- synthetase Ab
- raynaud
- ILD
- inflamm arth
🚨TIF1-gamma🚨
- ovarian CA (older, IgG2)
#ACR21 #ACRAmbassador
Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)
